Global Generic Cancer Drug Market Poised for Robust Growth, Driven by Rising Demand and Healthcare Investments

• Global generic oncology sterile injectable market projected to surge from $15.68B in 2023 to $17.61B in 2024, CAGR of 12.3% • Forecasted to reach $27.04B by 2028, CAGR of 11.3% due to rising healthcare investments and cancer incidence • North America is the largest market currently; Asia-Pacific is the fastest growing region • Key players include Pfizer, Johnson & Johnson, Novo Nordisk, Baxter International; strategic collaborations and new product launches underscore market's dynamic nature • Report offers in-depth analysis of market size, regional shares, competitive landscape, key segments, trends, and future projections